Nimotuzumab
- CAS No.
- 780758-10-3
- Chemical Name:
- Nimotuzumab
- Synonyms
- Nimotuzumab (anti-EGFR)
- CBNumber:
- CB54845998
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD00211841
- MOL File:
- Mol file
- MSDS File:
- SDS
| storage temp. | Store at -20°C |
|---|---|
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | 6NS400BXKH |
Nimotuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | BN165591 | Nimotuzumab | 780758-10-3 | 1mg | $1090.89 | 2026-06-04 | Buy |
| ChemScene | CS-0110992 | Nimotuzumab 96.80% | 780758-10-3 | 1mg | $607 | 2026-06-04 | Buy |
| ChemScene | CS-0110992 | Nimotuzumab 96.80% | 780758-10-3 | 5mg | $2112 | 2026-06-04 | Buy |
| ChemScene | CS-0110992 | Nimotuzumab 96.80% | 780758-10-3 | 10mg | $3033 | 2026-06-04 | Buy |
| aablocks | AA01V7CB | Nimotuzumab ≥95%(SDS-PAGE&SEC-HPLC) | 780758-10-3 | 1mg | $884 | 2026-05-31 | Buy |
Nimotuzumab Chemical Properties, Uses, Production
Description
Nimotuzumab(Taixinsheng) is a biologically targeted drug that acts on the epidermal growth factor receptor (EGFR) on the surface of tumor cells, inhibiting the proliferation and differentiation of tumor cells. It has the advantages of low reaction and good safety.
Suitable for head and neck tumors, gliomas, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, non-small cell lung cancer and other solid tumors.
Uses
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].
Pharmacology
Nimotuzumab, as the first humanized monoclonal antibody in my country, can competitively bind to EGFR and block its conduction pathway, thereby inhibiting tumor cell proliferation and tumor angiogenesis, thereby enhancing the efficacy of radiotherapy and chemotherapy.
target
EGFR
References
[1] Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382. DOI:10.3389/fphar.2017.00382
[2] Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8. DOI:10.4161/mabs.1.1.7509
Nimotuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Nimotuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Wuhan Topule | +86-02787215551 19945035818 | 2936752263@qq.com | China | 7983 | 58 |
| cjbscvictory | 13348960310 13348960310 | 3003867561@qq.com | China | 10233 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 | 2223443625@qq.com | China | 7998 | 58 |
| Wuhan Augda Biotechnology Co., Ltd | 15071299552 | 262933239@qq.com | China | 7201 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
